Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Latanoprost

FDA-approved product (solution/drops, ophthalmic), marketed as Iyuzeh, Latanoprost, Xalatan and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Latanoprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Hypertension
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Latanoprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Latanoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

    NCT04737928 · start 2018-04-02

    Registered record
    Registry ID
    NCT04737928
    Conditions
    Glaucoma, Primary Open Angle
    Interventions
    Latanoprost; tafluprost
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-04-02
    Completion
    2019-01-22
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Primary Open Angle
    InterventionLatanoprost; tafluprost
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost

    NCT03331770 · start 2017-01-06

    Registered record
    Registry ID
    NCT03331770
    Conditions
    Primary Open-angle Glaucoma
    Interventions
    Latanoprost Ophthalmic Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-06
    Completion
    2017-10-06
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open-angle Glaucoma
    InterventionLatanoprost Ophthalmic Product
    PhasePhase 4
    Registry statusCompleted

  • A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

    NCT02981446 · start 2017-01

    Registered record
    Registry ID
    NCT02981446
    Conditions
    Open Angle Glaucoma or Ocular Hypertension
    Interventions
    DE-117; Latanoprost ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01
    Completion
    2019-01
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma or Ocular Hypertension
    InterventionDE-117; Latanoprost ophthalmic solution
    PhasePhase 3
    Registry statusCompleted

  • A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

    NCT02622334 · start 2015-12-29

    Registered record
    Registry ID
    NCT02622334
    Conditions
    Glaucoma
    Interventions
    Latanoprost; Placebo; RO5093151
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12-29
    Completion
    2016-07-28
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionLatanoprost; Placebo; RO5093151
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

    NCT02167035 · start 2014-08

    Registered record
    Registry ID
    NCT02167035
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Combigan Two Times Daily (BID); Simbrinza Three Times Daily (TID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-08
    Completion
    2018-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionCombigan Two Times Daily (BID); Simbrinza Three Times Daily (TID)
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

    NCT02108288 · start 2014-04

    Registered record
    Registry ID
    NCT02108288
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    OPC-1085EL ophthalmic solution; Carteolol long-acting ophthalmic solution; Latanoprost ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionOPC-1085EL ophthalmic solution; Carteolol long-acting ophthalmic solution; Latanoprost ophthalmic solution
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension

    NCT02047630 · start 2014-01

    Registered record
    Registry ID
    NCT02047630
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Generic latanoprost; Brand-name latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-01
    Completion
    2014-12-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionGeneric latanoprost; Brand-name latanoprost
    PhasePhase 4
    Registry statusTerminated

  • Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

    NCT01896180 · start 2013-07

    Registered record
    Registry ID
    NCT01896180
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension; Elevated Intraocular Pressure
    Interventions
    ALZ-1101; Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension; Elevated Intraocular Pressure
    InterventionALZ-1101; Latanoprost
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertension

    NCT01987323 · start 2013-01

    Registered record
    Registry ID
    NCT01987323
    Conditions
    Ocular Hypertension
    Interventions
    Subconjunctival injection of liposomal latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension
    InterventionSubconjunctival injection of liposomal latanoprost
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy of Changing to TRAVATAN® From Prior Therapy

    NCT01493427 · start 2011-12

    Registered record
    Registry ID
    NCT01493427
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-02
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004%
    PhasePhase 4
    Registry statusCompleted

  • Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy

    NCT01426464 · start 2011-09

    Registered record
    Registry ID
    NCT01426464
    Conditions
    Glaucoma
    Interventions
    0.005% Latanoprost dosed once.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2011-12
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Intervention0.005% Latanoprost dosed once.
    PhasePhase 2
    Registry statusUnknown

  • Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

    NCT01162603 · start 2011-03

    Registered record
    Registry ID
    NCT01162603
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Goldmann and Perkins applanation tonometry; TAFLUPROST 0.0015% EYEDROPS; LATANOPROST 0.005% EYEDROPS
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionGoldmann and Perkins applanation tonometry; TAFLUPROST 0.0015% EYEDROPS; LATANOPROST 0.005% EYEDROPS
    PhasePhase 4
    Registry statusCompleted

  • A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

    NCT01229982 · start 2010-10

    Registered record
    Registry ID
    NCT01229982
    Conditions
    Ocular Hypertension; Open Angle Glaucoma
    Interventions
    Latanoprost-PPDS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-08
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open Angle Glaucoma
    InterventionLatanoprost-PPDS
    PhasePhase 2
    Registry statusCompleted

  • The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma

    NCT01369771 · start 2010-08

    Registered record
    Registry ID
    NCT01369771
    Conditions
    Ocular Hypertension; Open-Angle Glaucoma
    Interventions
    Tafluprost 0.0015%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-Angle Glaucoma
    InterventionTafluprost 0.0015%
    PhasePhase 4
    Registry statusCompleted

  • 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice

    NCT01448837 · start 2010-04

    Registered record
    Registry ID
    NCT01448837
    Conditions
    Glaucoma
    Interventions
    Bimatoprost/Timolol, 24-hour intraocular pressure monitoring; Latanoprost, 24-hour intraocular pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-04
    Completion
    2011-03
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionBimatoprost/Timolol, 24-hour intraocular pressure monitoring; Latanoprost, 24-hour intraocular pressure monitoring
    PhasePhase 4
    Registry statusCompleted